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of P-glycoprotein in the resistance of canine
osteosarcoma to chemot,herapy will be investigated.
The researchers hope to expand the project so that
they can evaluate different clinical protocols in dogs
with osteosarcoma and assess prognostic indicators
and chemosensitivity assays to predict differences in

Treatment of Canine
Osteosarcoma
Each year about 10,000 dogs in the United
States, mostly of the large and giant breeds, are
diagnosed with osteos arcom a (OSA), a painful bone
tumor. This disease also occurs in humans, though
not in such high numbers. Osteo sar coma in dogs
affects primarily the long bones of the leg, but can
affect bones of the spine, skull, or ribs.
"Over the last ten years there have been major
advances in treatment of this disease in both
species.'' said Dr. M. Joy Weinstein, assistant
professor of surgery at Peon's School of Veterinary
Medicine, ''but better treatment protocols are still
needed. Therapy for osteosarcoma of long bones
includes amputation with or without chemotherapy,
or limb-sparing surgery and chemotherapy. Limb
sparing surgery involves removal of the primary
tu mor while preserving the limb through use of a
bone graft or a prosthesis. Two chemotherapy drugs
that appear to be most effective in this disease are
adriamycin and cisplatin. Unfortunately, at this
point in time, we cannot cure the disease, but we can
give the dog a good quality of life for a number of
months or years."
Dr. Weinstein, who returned to Penn after
surgical specialty training at Tufts University School
of Veterinary Medicine, is c onduct ing a study
assessing perioperative and postoperative treatment
of OSA by administering adriamycin and ci sp latin
concurrently. ''These drugs usually are used alone or
alter nate d to reduce the growth of metastases. By
administering them together we hope to achieve an.
additive effect."
Osteosarcoma in dogs frequently manifests itself
as a limp; the dog is in pain and often refuses to use
I he leg. Radiographs reveal a bone LUmor at the end
of the long bone of the leg, either front or rear.
'·When the animal comes to t he veterinarian, the
tumor has already spread through mkroscopic
lesions to other parts of the body, primarily the
lung," said Dr. Weinstein. "If we amputate rhe leg
and give no other treatment, the median survival time
is about 18 weeks, though some dogs (10 percent) live
more than a year. Jf the animal is treated with
chemotherapy, either cisplati n or adriamycin, the
median survival time increases to about 40-45 weeks,
with nearly 50% of the dogs living more than a
year."
Amputation of the affected limb is Dr.
Weinstein's preferred surgical treatment. "It reli eves
the pain and the dog can ge t around quite well on
three legs," she explained. ''Most dogs walk one day
after surgery and need exercise restrictions for only
about LWO weeks." An alternative to amputation is
limb sparing surgery. She recommends this treatment
for dogs that would not get around well on three legs
or those cases where an owner cannot accept
amputation as an option for the dog. Here the tumor
and the affected section of bone are removed� and a
bone graft is used to replace the missing bone. The
graft can be donor bone which has beeu frozen an d
stored, but infections are comm on with this method.
Dr. Mark Cofone and Dr. David Diefenderfer have

used autogenous, cancellous bone as the graft. Small
amounts of the soft bone from the marrow cavity of
the dog's own shoulder (proximal humerus), pelvis
(ilium) or knee (proximal tibia) are used to replace
the diseased bone. Plates and screws hold the bones
in their proper orientation. It is complicated surgery
and the time period until the bone graft has healed
may be several months. Limb-sparing surgery is most
successful for tumors of the distal radius (lower
foreleg) because the carpal joint (wrist) can be fused
without problems.

Previously described chemorherapy treatment
protocols for OSA incorporate cisptatin and/or
adriamycin, usually given at three week intervals.
The drugs are administered intravenously. They are
both potent drugs that act on cell division.
Adriamycin prevents DNA from replicating, thus
slowing the growth of metastasized tumors. Cisplatin
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the response to treatment.
nr. Weinstein is currently searching for funding
for the chemotherapy study from priva te sources or
foundations to support the costs of the drugs.
Without support, surgery and the chemotherapy
drugs cost about $2,000 per patient. If support can be
found, Lhese costs to the clients will decrease
considerably. Dr. Weinstein is also looking for
candidates for the treatment and she hopes that
veterinarians with canine osteosarcoma patients will
refer them to the Veterinary Hospital of the
University of Pennsylvania.

Or. Joy Weinstein and one of her pa t ienrs, a
nine·year old Rottweiler who had his foreleg
amputated.

Cisplatin and adriamycin were

administered perioperatively, followed by two
additional treatments three weeks apart. Tbe dog is
doing well and quite active.

also affects the DNA, binding to it. crosslinking the
strands. Both drugs affect other rapidly growing cells
in the body, such as bone marrow cells and intestinal
cells. Side effects are often minimal, but can include
decreased appetite, gastrointestinal upset, bone
marrow suppression, kidney p roble ms , or heart
problems.
Dr. Weinstein proposes lO use the two drugs
concurrently, administering therapeutic doses of
cisplatin and slightly lower doses of adriamycin to
fur1her slow down metastatic tumor growth.
Preliminary studies have shown encouraging results,
four dogs 1 rea ted are doing well six to ten months
after Lreatment. She proposes to use the drugs
postoperatively, beginning two weeks after surgery,
in one group of patiems for a total of three cydes,
three weeks apan. In another group of patien ts, the
first dose of drugs wm be administered
perioperatively, within 14 hours after surgery,
followed by two additional treatments three weeks
apart. "Studies in humans and rodents have shown
that there is rapid growth of metastatic lesions in
these species following surgical excision of primary
tumors," she srud. "Studies in laboratory animal
tumor models show that administration of
peri operative chemotherapy prevents a rapid growth
phase in me tas tatic lesions following removal of the
p rim ary tumor.'' Dr. Wdnstein explained that
perioperative chemotherapy is not routinely
administered t o humans with the disease due to fear
of postoperative surgical wound complications, such
as infections and delayed wound healing. "Our
previous results administering pre-, perioperative and
postoperative adriamycin to dogs with osteosarcoma
do not support high wound complication rates. We
hope to document improved survival rates for
patients treated with perioperative chemotheupy;
this woul.d advance canine osteosarcoma treatment
and might also encourage similar studies in human
patients with the disease.''
Osteosarcoma in people is a d isease of teenagers
and young adults. In dogs it affects primarily
middle-aged animaJs, though it does occur in dogs
under two years of age and in elderly dogs. Canine
osteosarcoma may serve as a model for human
osteosarcoma and Dr. Weinstein is collaborating
with researchers at the Medical SchooJ on several
projects. "We are looking at MRL images of the
amputated canine limb to establish how the tumor
margins seen on the image correspond to the tumor
margins estab lished by histological examination."
she explained. "lt is very difficult for the surgeon,
when doing limb-sparing surgery on people or dogs,
to know eJCact!y where the lumor ends," she said.
"We hope to determine jusl how accurate the MRI
scan is In defining the tumor margins." The studies
also encompass a look at the role of growth factors
and their receptors in canine osteosarcoma. The role

Dr. Weinstein graduated from the University of
Pennsylvania School of Veterinary Medicine in 1983;
s he completed a surgery residency at Tufts University
School of Veterinary Medicine and Angell Memorial
Animal Hospital; and be.came an instruc t or in
surgery at Tufts. She completed a research fellowship
at Massachusetts Genefal Hospital where she worked
in the laboratory of Dr. Henry Mankin. a pioneering
researcher in bone cancer in people.

Merck Supports
Laboratory Animal
Medicine Training
Merck Sharp & Dohme Research Laboratories
Djvision of Merck & Co., Inc. has provided a
postdoctoral fellowship grant h1 Laboratory Animal
Medicine at the Universi1y of Pennsylvania. Dr.
Laurence Handt, a 1987 veterinary graduate of
Mi�.:higan State University, has been selected as the
first recipient of the grant and is now in the first year
of the program. The laboratory animal medicine
program has been in existence since 1987 at the
University of Pennsylvania. It is a three-year
program combining a residency in laboratory animal
medicine with a master's degree in a related scientific
discipline. Individuals enrolled in this program also
complete a one-month rotation in c he Department of
Laboratory Animal Resources at Merck's West
Point, PA facility. This program is designed to
develop competence in biomedical research and
laboratory animal medicine, and prepare candidates
for the American College of Laboratory Animal
Medicine board certification. This joint effort of
Merck and the U niversity of Pennsylvania is an
example of the growing trend of the business sector

pr oviding financial assistance to foster advanced
training in scientific disciplines.

Shown here (left to rigbt) a re Dr. Harry Rozmiarek,
director of t.he University of Pennsyl\'ania Office of
Unive rsity Laboratory Animal Resources and
director ot the Laboratory Animal Medicine
Training Program, Or. Jeffrey Linn, associate
dirertor and clinical coordinator, Dr. L aure nce
Handt, Or. Gwendolyn McCormick, staff
veterinarian with Merck's Department of Laboratory
Animal Resources at West Point, PA and Dr. Hilton
Klein, direc tor of Laboratory Animal Resources,
MSORL Division of Merck.

